Nwogo Ajuka Obasi

Dr. Nwogo Ajuka Obasi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
CAChinyere Aloke
Chinyere Aloke
CEChinedu Ogbonnia Egwu
Chinedu Ogbonnia Egwu
PAPatrick Maduabuchi Aja
Patrick Maduabuchi Aja
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
JCJennifer Ifeoma Chukwu
Jennifer Ifeoma Chukwu
IAIkechukwu Achilonu
Ikechukwu Achilonu
Diabetes mellitus (DM) underscores a rising epidemic orchestrating critical socio-economic burden on countries globally. Different treatment options for the management of DM are evolving rapidly because the usual methods of treatment have not completely tackled the primary causes of the disease and are laden with critical adverse effects. Thus, this narrative review explores different treatment regimens in DM management and the associated challenges. A literature search for published articles on recent advances in DM management was completed with search engines including Web of Science, Pubmed/Medline, Scopus, using keywords such as DM, management of DM, and gene therapy. Our findings indicate that substantial progress has been made in DM management with promising results using different treatment regimens, including nanotechnology, gene therapy, stem cell, medical nutrition therapy, and lifestyle modification. However, a lot of challenges have been encountered using these techniques, including their optimization to ensure optimal glycemic, lipid, and blood pressure modulation to minimize complications, improvement of patients’ compliance to lifestyle and pharmacologic interventions, safety, ethical issues, as well as an effective delivery system among others. In conclusion, lifestyle management alongside pharmacological approaches and the optimization of these techniques is critical for an effective and safe clinical treatment plan.

3 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CAChinyere Aloke
Chinyere Aloke
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
PAPatrick Maduabuchi Aja
Patrick Maduabuchi Aja
CEChinedum Uche Emelike
Chinedum Uche Emelike
CEChinedu Ogbonnia Egwu
Chinedu Ogbonnia Egwu
IAIkechukwu Achilonu
Ikechukwu Achilonu
Lassa fever (LF) is a rodent-borne disease that threatens human health in the sub-region of West Africa where the zoonotic host of Lassa virus (LASV) is predominant. Currently, treatment options for LF are limited and since no preventive vaccine is approved for its infectivity, there is a high mortality rate in endemic areas. This narrative review explores the transmission, pathogenicity of LASV, advances, and challenges of different treatment options. Our findings indicate that genetic diversity among the different strains of LASV and their ability to circumvent the immune system poses a critical challenge to the development of LASV vaccines/therapeutics. Thus, understanding the biochemistry, physiology and genetic polymorphism of LASV, mechanism of evading host immunity are essential for development of effective LASV vaccines/therapeutics to combat this lethal viral disease. The LASV nucleoprotein (NP) is a novel target for therapeutics as it functions significantly in several aspects of the viral life cycle. Consequently, LASV NP inhibitors could be employed as effective therapeutics as they will potentially inhibit LASV replication. Effective preventive control measures, vaccine development, target validation, and repurposing of existing drugs, such as ribavirin, using activity or in silico-based and computational bioinformatics, would aid in the development of novel drugs for LF management.

1 January 2021 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
CAChinyere Aloke
Chinyere Aloke
UIU.A. Ibiam
U.A. Ibiam
OOO.U. Orji
O.U. Orji
EUE.I. Ugwuja
E.I. Ugwuja
NEN.N. Ezeani
N.N. Ezeani
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
Traditional medicine intervention has been used in rheumatoid arthritis (RA) treatment due to limitations of conventional drugs. This study aimed at evaluating the anti-arthritic potentials of ethanol and aqueous extracts of stem bark of Cleistopholis patens (SBCP) in complete Freund's adjuvant (CFA) induced rheumatoid arthritis in rats. Rheumatoid arthritis was induced in groups 2 to 9 by intradermal injection of 0.1 mlkg-1 chicken type II collagen in CFA into the left hind paw of the rats. Group 1 served as normal control. Group 2 (negative control) received 5 mlkg-1 body weight normal saline while group 3 (positive control) received 10 mg/kg body weight standard drug (indomethacin). Groups 4 to 9 received varied doses of the extracts. After 10 days of RA induction, rats were treated with ethanol and aqueous extracts of SBCP orally at a dose of 400, 600 and 800 mgkg-1 for 21 days. The paw size, body weight changes, inflammatory parameters, lipid peroxidation maker and malondialdehyde (MDA) were assessed. Rheumatoid arthritis induction caused marked (p < 0.05) increase in paw size, inflammatory makers and MDA while significant (p < 0.05) reduction was observed in body weight relative to normal control. Treatment with extracts analogous to indomethacin markedly (p < 0.05) decreased the paw size and caused weight gain while the altered inflammatory parameters and MDA were reversed relative to negative control. The findings suggest that the extracts of SBCP have good antiarthritic potentials comparable to indomethacin and hence could be used in rheumatoid arthritis management.

1 October 2019 in Toxicology Mechanisms and Methods
Verified
Journal Article
Closed access
Ademola C. FamurewaAdemola C. Famurewa
Ademola C. Famurewa
CEChima A. Ekeleme-Egedigwe
Chima A. Ekeleme-Egedigwe
EDEbuka Elijah E. David
Ebuka Elijah E. David
CEChinedum O. Eleazu
Chinedum O. Eleazu
AFAbiola M. Folawiyo
Abiola M. Folawiyo
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
Tamoxifen (TAM) is used in breast cancer chemotherapy since its approval by the Food and Drug Administration in 1977. However, TAM therapy is accompanied with hepatotoxicity- a source of worry to clinicians. Oxidative stress and inflammation are the major implicated mechanisms contributing to TAM hepatotoxicity. In this study, we explored whether zinc (Zn) supplementation could prevent TAM-induced hepatotoxicity in female Wistar rats. Rats were subjected to oral pretreatment of Zn (100 mg/kg body weight (b.w.)/day) for 14 days against hepatic toxicity induced by single intraperitoneal administration of TAM (50 mg/kg b.w.) on day 13. TAM markedly elevated serum liver enzymes, whereas total protein and albumin considerably reduced. TAM caused prominent depletion of hepatic reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) activity. Also, TAM significantly increased malondialdehyde (MDA) level. Further, it raised liver levels of tumor necrosis factor-α (TNF-α), interleukin-1β, (IL-1β), interleukin-6 (IL-6), and nitric oxide (NO) confirmed by the liver histopathological alterations. The mechanistic inflammatory expression of inducible nitric oxide synthase (iNOS) and nuclear factor-kappa B (NF-ĸB), and expression of caspase-3 protein prominently increased. Zinc supplementation significantly modulated serum liver function markers, antioxidant enzymes, GSH and MDA levels. Zinc downregulated the expression of cytokines, NO, iNOS, NF-ĸB and caspase-3, and ameliorated histopathological changes. Zinc protects against TAM-induced hepatotoxicity; it may serve as an adjuvant supplement for female patients undergoing TAM chemotherapy.

15 December 2011 in Pakistan Journal of Biological Sciences
Verified
Journal Article
Closed access
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
JUJoy Ukadilonu
Joy Ukadilonu
EEEberechukwu Eze
Eberechukwu Eze
EAE.I. Akubugwo
E.I. Akubugwo
UOU.C. Okorie
U.C. Okorie
Proximate Composition, Extraction, Characterization and Comparative Assessment of Coconut (Cocos nucifera) and Melon (Colocynthis citrullus) Seeds and Seed Oils

18 April 2020 in Environmental Monitoring and Assessment
Verified
Journal Article
Closed access
PDF file
NONwogo Ajuka Obasi
Nwogo Ajuka Obasi
SOS. E. Obasi
S. E. Obasi
ENE. Nweze
E. Nweze
SAS. O. Amadi
S. O. Amadi
CAC. Aloke
C. Aloke
GAG. O. Aloh
G. O. Aloh